Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis
Conclusions: PCI might be associated with a favorable survival advantage and reduced BM risk in complete resected SCLC patients, except for p-stage I patients.
ConclusionsTRT provided significant PFS and OS benefits in patients with oligometastatic ES-SCLC without brain or liver involved. The consolidative TRT is a reasonable treatment option for this favorable patient population.
We report a case of a patient with chronic inflammatory rheumatism, psoriasis and Hashimoto thyroiditis and subsequent appearance of static and dynamic ataxia and episodic memory deficit who was diagnosed as PLE combined with small cell lung cancer (SCLC). Diagnoses: The diagnosis of SCLC was made with EBUS-TBNA of a mediastinal lymph node. Interventions: Whole-body 18F-FDG PET/CT was performed for the initial staging of SCLC, in the planning of radiotherapy treatment, to evaluate therapeutic response and in the follow-up. A dedicated brain scan was included to the same PET session. Whole-body contrast enhanced compu...
This study evaluated an association between whole brain volume loss and neurocognitive decline following prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (SCLC).MethodsThis was a secondary analysis of a prospective clinical trial that accrued patients at a single institution from 2013 to 2016. Patients with limited-stage SCLC treated with standard chemo-radiation received PCI 25 Gy/10 fractions, with mean hippocampal dose limited to
ConclusionOverall, PCI was associated with improved PFS and reduced early incidence of brain metastases. Patients achieving a CR to initial therapy did not experience a PFS benefit with PCI. This may indicate that subsets of LS-SCLC patients can potentially be spared from PCI in the era of modern imaging.
In this study, we reported the case of a 74-year-old Japanese woman who developed PLE after partial remission of small cell lung cancer (SCLC) by first-line systemic chemotherapy. Brain magnetic resonance imaging showed no metastatic tumor or cerebrovascular disease. Anti-glutamic acid decarboxylase (GAD) and anti-amphiphysin antibodies were detected in her serum. She was diagnosed as having PLE related to the recurrence of SCLC and received high-dose glucocorticoid, and sequentially systemic chemotherapy with amrubicin. Unfortunately, these treatments did not improve her disease progression and she died 4 months later. Al...
ConclusionIn this experience neither prior PCI nor WBRT improved survival or local tumor control in SCLC patients who underwent SRS for new or recurrent brain disease.
Background: Studies on prognosis of different metastasis sites in patients with lung cancer are limited. The aim of present study was to investigate the prognostic value of metastases sites among patients with metastatic lung cancer.Methods: Between 2010 and 2014, patients diagnosed with metastatic lung cancer were selected using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier methods were adopted and multivariable Cox regression models were built to compare the prognosis of different metastasis sites.Results: A total of 54,697 eligible patients were identified, including 10,945 (20.0%) patien...
In patients treated for small-cell lung cancer (SCLC) in China, twice-daily radiotherapy was associated with more brain metastases than once-daily radiation, a retrospective study found.Reuters Health Information
In conclusion, KRAS exon 3 and PTEN exon 7 mutations had no significant impact on OS of SCLC patients. Further study is still necessary to validate the molecular profiles of SCLC.
In conclusion, ED-SCLC with metastasis limited to the brain could be treated with curative intent.